SEATTLE, December 11, 2019-- AGC Biologics, a global Contract Development and Manufacturing Organization (CDMO) for Biopharmaceuticals, is significantly expanding its CDMO services with plasmid DNA (pDNA) offerings from its Heidelberg site in Germany. With the demand for pDNA growing rapidly, AGC Biologics is leveraging 25 years of experience and comprehensive in-house analytics development to ensure customers short and dependable timelines.
Recent Posts by Diane Hunt:
We hope to see you at BIO Japan in Yokohama, Japan on October 14 - 16, 2020.
We're looking forward to attending cPHI in Milan, Italy.
Will you be joining us there? Let us know if you'd like to meet. Email us at email@example.com.
17,000+ attendees from around the globe will gather for BIO 2020. This is a great opportunity for unparalleled partnering, education and networking. Look for us in the BioProcess Zone, Booth 1111 in the San Diego Convention Center.
The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry.
In 2020 there will likely be 450+ companies, both public and private, delivering presentations to more than 9,000 attendees.
See you in San Francisco!
SEATTLE, WA -- November 11th, 2019 -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today that their development and manufacturing capabilities at their Seattle, Washington and Copenhagen, Denmark facilities will be expanded, as part of an ongoing commitment to deliver the highest standard of service for their customers.
Jeffrey D. Mowery Named Site Head/General Manager
Naofumi Kagami Named Site Head/General Manager
Kasper Møller named Chief Technical Officer